The high cumulative genetic risks incurred by pathogenic BRCA1/2 variants paved the way for rapid founder variant testing as the first step to increase access to cancer genetic testing in South Africa and to reduce loss to follow-up (8, 16). Here, BRCA1 is linked to cancer.